TG Therapeutics (TGTX) Tops Q2 EPS by 21c

TG Therapeutics (NASDAQ: TGTX) reported Q2 EPS of ($0.30), $0.21 better than the analyst estimate of ($0.51). Revenue for the quarter came in at $594 thousand versus the consensus estimate of $175.43 thousand.

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M